PD-1与CTLA-4联合阻断治疗肢端雀斑样黑色素瘤的国际队列研究
这项多机构回顾性研究分析了2010至2022年间109例组织学确诊的晚期肢端雀斑样黑色素瘤(ALM)患者,接受PD-1与CTLA-4抑制剂联合治疗。客观缓解率(ORR)为18.3%(95%CI 11.6-26.9),中位无进展生存期(PFS)4.2个月(95%CI 3.25-5.62),中位总生存期(OS)17个月(95%CI 12.4-23.1)。结论认为该联合方案对ALM的疗效低于皮肤黑色素瘤(CM),尤其亚洲患者获益更少,需探索新疗法。
要点
- 联合免疫治疗在晚期ALM中ORR仅18.3%,远低于CM的历史数据。
- 中位PFS 4.2个月,中位OS 17个月,生存获益有限。
- 87.2%患者出现治疗相关不良事件,40.4%发生≥3级毒性。
核心结论
- PD-1与CTLA-4联合阻断对ALM的疗效低于CM,尽管毒性相似。
- 亚洲患者似乎从该方案中获益更少,需要新型治疗策略。
研究设计与样本
- 多机构回顾性研究,纳入2010至2022年间组织学确诊的ALM患者。
- 共109例接受PD-1与CTLA-4抑制剂联合治疗的晚期ALM患者,任意治疗线数。
- 主要终点为按RECIST标准的客观缓解率(ORR),次要终点为PFS和OS。
主要发现
- 全队列ORR为18.3%(95%CI 11.6-26.9),其中完全缓解9例(8.3%),部分缓解11例(10.1%)。
- 疾病稳定22例(20.2%),疾病控制率38.5%。
- 中位PFS为4.2个月(95%CI 3.25-5.62),中位OS为17个月(95%CI 12.4-23.1)。
- 95例(87.2%)发生治疗相关不良事件,44例(40.4%)发生至少1次3或4级毒性。
- 乳酸脱氢酶升高(P=0.04)、既往≥2线治疗(P=0.03)和亚洲种族(P=0.04)与更差OS相关,西班牙裔/拉丁裔种族与更好OS相关(P=0.02)。
临床怎么用
- 对晚期ALM患者使用PD-1联合CTLA-4阻断时,应预期ORR约18.3%、中位PFS约4.2个月和中位OS约17个月。
- 亚洲ALM患者可能从该联合方案中获益更少,临床决策需个体化。
- 该方案毒性显著,87.2%发生治疗相关不良事件,40.4%发生≥3级毒性,需密切监测。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- 样本量有限(109例),亚组分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) leads to high response rates and improved survival in patients with advanced cutaneous melanoma (CM). Less is known about the efficacy of this combination in acral lentiginous melanoma (ALM). OBJECTIVES: To determine the efficacy of combination immune checkpoint blockade targeting PD-1 and CTLA-4 in a diverse, real-world population of patients with ALM. METHODS: This multi-institutional retrospective study analysed patients with histologically confirmed ALM treated with a combination of PD-1 and CTLA-4 inhibitors between 2010 and 2022. The primary objective of the study was the objective response rate (ORR) as per the RECIST criteria. The secondary objectives were progression-free survival (PFS) and overall survival (OS). RESULTS: In total, 109 patients with advanced ALM treated with combined PD-1 and CTLA-4 blockade in any line of treatment were included. The majority of patients had stage IV disease (n = 81; 74.3%). The ORR for the entire cohort was 18.3% [95% confidence interval (CI) 11.6-26.9], with 9 (8.3%) complete and 11 (10.1%) partial responses. A further 22 patients (20.2%) had stable disease, and the disease control rate was 38.5%. Median PFS was 4.2 months (95% CI 3.25-5.62), while median OS was 17 months (95% CI 12.4-23.1). Ninety-five patients (87.2%) had a treatment-related adverse event, with 40.4% (n = 44/109) experiencing at least one grade 3 or 4 toxicity. Elevated lactate dehydrogenase (P = 0.04), ≥ 2 lines of prior treatment (P = 0.03) and Asian ethnicity (P = 0.04) were associated with worse OS, while Hispanic/Latino ethnicity was associated with better OS (P = 0.02). CONCLUSIONS: Combination PD-1 and CTLA-4 blockade is less effective for ALM than for CM, despite similar toxicity. In particular, Asian patients appear to derive less benefit from this regimen. Novel treatment approaches are needed for this rare melanoma subtype. Melanoma is an aggressive type of skin cancer that affects more than 325,000 people worldwide every year. Acral lentiginous melanoma (or ‘ALM’ for short) is rare type of melanoma that appears on the palms of the hands, soles of the feet or in nailbeds. Unusually, it is not thought to be caused by exposure to the sun, unlike most other skin melanomas. Medications that use the body’s own immune system to fight cancer are very effective against advanced melanoma that is no longer suitable for surgery. This is called ‘immunotherapy’. Two thirds of people with advanced skin melanomas had their tumours shrink when they were treated with two immunotherapy medications used together. Immunotherapy appears to be less effective in ALM, but research has been very limited. In our international study that included more than 100 patients from multiple cancer centres, we looked at how effective two immunotherapy drugs were when used together against ALM in people whose cancer was advanced. We found that ALM is not as responsive to these two drug combinations when compared with other skin melanomas. Only about 2 in 10 patients with ALM in the study had their tumours decrease in size. We also found that combination immunotherapy had limited benefit on patients’ survival. Most cancers came back after about 4 months and led to patients dying after about 17 months. Our results suggest that combination immunotherapy is not very effective in ALM. New treatment options must be explored.
引用
- McGillivray E, Ashouri K, Chatziioannou E, et al. Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma. Br J Dermatol. 2025. PMID: 39438074. doi:10.1093/bjd/ljae401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。